BitMEX co-founder Arthur Hayes says he has re-entered his Hyperliquid (NASDAQ:PURR) trade, predicting the asset could surge more than fourfold if the p
As pharmaceutical companies race to develop treatments for metabolic dysfunction–associated steatohepatitis (MASH) and related steatotic liver disease (SLD), one critical piece of the healthcare puzzle is drawing increasing attention: how to diagnose and monitor millions of patients at scale . While most investor focus remains on drug developers, ENDRA Life Sciences (NASDAQ: NDRA) is positioning itself on the infrastructure side of the emerging MASH ecosystem with its innovative TAEUS® (Thermo-Acoustic Enhanced UltraSound) liver imaging technology.
